Cargando…
Pancreatic islet organoids-on-a-chip: how far have we gone?
Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238112/ https://www.ncbi.nlm.nih.gov/pubmed/35764957 http://dx.doi.org/10.1186/s12951-022-01518-2 |
_version_ | 1784736957464576000 |
---|---|
author | Yin, Jiaxiang Meng, Hao Lin, Jingfang Ji, Wei Xu, Tao Liu, Huisheng |
author_facet | Yin, Jiaxiang Meng, Hao Lin, Jingfang Ji, Wei Xu, Tao Liu, Huisheng |
author_sort | Yin, Jiaxiang |
collection | PubMed |
description | Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the research and treatment of DM, the platforms have been widely used to investigate the physiology and pathophysiology of islets. In this review, we first highlight how pancreatic islet organoids-on-a-chip have improved the reproducibility of stem cell differentiation and organoid culture. We further discuss the efficiency of microfluidics in the functional evaluation of pancreatic islet organoids, such as single-islet-sensitivity detection, long-term real-time monitoring, and automatic glucose adjustment to provide relevant stimulation. Then, we present the applications of islet-on-a-chip technology in disease modeling, drug screening and cell replacement therapy. Finally, we summarize the development and challenges of islet-on-a-chip and discuss the prospects of future research. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9238112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92381122022-06-29 Pancreatic islet organoids-on-a-chip: how far have we gone? Yin, Jiaxiang Meng, Hao Lin, Jingfang Ji, Wei Xu, Tao Liu, Huisheng J Nanobiotechnology Review Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the research and treatment of DM, the platforms have been widely used to investigate the physiology and pathophysiology of islets. In this review, we first highlight how pancreatic islet organoids-on-a-chip have improved the reproducibility of stem cell differentiation and organoid culture. We further discuss the efficiency of microfluidics in the functional evaluation of pancreatic islet organoids, such as single-islet-sensitivity detection, long-term real-time monitoring, and automatic glucose adjustment to provide relevant stimulation. Then, we present the applications of islet-on-a-chip technology in disease modeling, drug screening and cell replacement therapy. Finally, we summarize the development and challenges of islet-on-a-chip and discuss the prospects of future research. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2022-06-28 /pmc/articles/PMC9238112/ /pubmed/35764957 http://dx.doi.org/10.1186/s12951-022-01518-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Yin, Jiaxiang Meng, Hao Lin, Jingfang Ji, Wei Xu, Tao Liu, Huisheng Pancreatic islet organoids-on-a-chip: how far have we gone? |
title | Pancreatic islet organoids-on-a-chip: how far have we gone? |
title_full | Pancreatic islet organoids-on-a-chip: how far have we gone? |
title_fullStr | Pancreatic islet organoids-on-a-chip: how far have we gone? |
title_full_unstemmed | Pancreatic islet organoids-on-a-chip: how far have we gone? |
title_short | Pancreatic islet organoids-on-a-chip: how far have we gone? |
title_sort | pancreatic islet organoids-on-a-chip: how far have we gone? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238112/ https://www.ncbi.nlm.nih.gov/pubmed/35764957 http://dx.doi.org/10.1186/s12951-022-01518-2 |
work_keys_str_mv | AT yinjiaxiang pancreaticisletorganoidsonachiphowfarhavewegone AT menghao pancreaticisletorganoidsonachiphowfarhavewegone AT linjingfang pancreaticisletorganoidsonachiphowfarhavewegone AT jiwei pancreaticisletorganoidsonachiphowfarhavewegone AT xutao pancreaticisletorganoidsonachiphowfarhavewegone AT liuhuisheng pancreaticisletorganoidsonachiphowfarhavewegone |